Tesaro appoints new board member
This article was originally published in Scrip
Oncology-focused biopharmaceutical company, Tesaro, has appointed Dr James Armitage to its board of directors – increasing the number of independent directors on the board to six. Dr Armitage is currently the Joe Shapiro chair for the study of oncology and clinical research at the University of Nebraska Medical Center, Omaha. He has also served as president of the American Society of Clinical Oncology and the American Society for Blood and Marrow Transplantation.